Filtros de búsqueda

Lista de obras de Mario E Lacouture

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

artículo científico publicado en 2016

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

artículo científico publicado en 2015

A comparison of type I collagen, fibronectin, and vitronectin in supporting adhesion of mechanically strained osteoblasts

artículo científico publicado en 2002

A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

artículo científico publicado en 2009

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

artículo científico publicado en 2017

A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia

artículo científico publicado en 2020

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

artículo científico publicado en 2016

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

artículo científico publicado en 2010

A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash

artículo científico publicado en 2017

A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

artículo científico publicado en 2015

Acneiform rash as a reaction to radiotherapy in a breast cancer patient

artículo científico publicado en 2010

Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series

artículo científico publicado en 2014

Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.

artículo científico

Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.

artículo científico publicado en 2006

Alopecia in patients treated with molecularly targeted anticancer therapies.

artículo científico publicado en 2015

Alopecia with endocrine therapies in patients with cancer.

artículo científico publicado en 2013

An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.

artículo científico publicado en 2008

Analysis of dermatologic events in patients with cancer treated with lapatinib.

artículo científico publicado en 2008

Anticancer therapy-induced adverse events: practicing damage control

artículo científico publicado en 2012

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

artículo científico publicado en 2012

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program

artículo científico publicado en 2016

Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011; 22(10): 2191-2200.

artículo científico publicado en 2013

Blackberry-induced hand-foot skin reaction to sunitinib

artículo científico publicado en 2008

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

artículo científico publicado en 2016

Characteristics of oral mucosal events related to bevacizumab treatment.

artículo científico publicado en 2012

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.

scientific article published on 10 August 2016

Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma

artículo científico publicado en 2014

Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.

artículo científico publicado en 2012

Clinical management of EGFRI dermatologic toxicities: US perspective

artículo científico publicado en 2007

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

artículo científico publicado en 2011

Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group.

artículo científico publicado en 2013

Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.

artículo científico publicado en 2011

Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.

artículo científico publicado en 2014

Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials

artículo científico publicado en 2008

Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists

artículo científico publicado en 2014

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern

artículo científico publicado en 2017

Cutaneous and mucosal reactions to oncologic therapy

artículo científico publicado en 2011

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).

artículo científico

Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

artículo científico publicado en 2014

Cyclophosphamide-associated acneiform drug eruption in a patient with multiple myeloma

artículo científico publicado en 2011

Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.

artículo científico publicado en 2015

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, And Management Guidelines

scientific article published on 05 October 2020

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.

artículo científico publicado en 2013

Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.

artículo científico publicado en 2015

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

artículo científico publicado en 2020

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice

artículo científico publicado en 2017

Dermatologic infections in cancer patients

artículo científico

Dermatologic issues in adult survivors of childhood cancer.

artículo científico publicado en 2009

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

artículo científico publicado en 2010

Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae.

artículo científico publicado en 2007

Dermatologic toxicities of targeted anticancer therapies.

scientific article published on July 2010

Dermatological adverse events from BRAF inhibitors: a growing problem.

artículo científico publicado en 2013

Dermatological adverse events with taxane chemotherapy

artículo científico publicado en 2016

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

artículo científico publicado en 2008

Dermoscopic findings in cutaneous metastases

scientific article published on 01 April 2014

Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer

artículo científico publicado en 2016

Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.

artículo científico publicado en 2014

Diagnosis of blue nevus-like metastatic uveal melanoma confirmed by fluorescence in situ hybridization (FISH) for monosomy 3.

artículo científico publicado en 2012

Differential radiation dermatitis in native skin and an autologous transplanted myocutaneous flap.

artículo científico publicado en 2014

Disseminated Mycobacterium marinum infection in a hematopoietic stem cell transplant recipient

artículo científico publicado en 2011

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

artículo científico publicado en 2015

EMPACT syndrome: limited evidence despite a high-risk cohort

artículo científico publicado en 2014

Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents

artículo científico publicado en 2011

Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.

artículo científico publicado en 2017

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life

artículo científico publicado en 2010

Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.

artículo científico publicado en 2014

Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature

scientific article published on 15 October 2019

Eosinophilic rash secondary to temsirolimus.

artículo científico publicado en 2009

Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma.

artículo científico publicado en 2010

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

artículo científico publicado en 2007

Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.

artículo científico publicado en 2017

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

scientific article published on 08 September 2008

Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events

artículo científico publicado en 2013

Gadolinium-associated nephrogenic systemic fibrosis.

artículo científico publicado en 2008

Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.

artículo científico publicado en 2012

Granuloma annulare associated with immune checkpoint inhibitors

artículo científico publicado en 2017

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

artículo científico publicado en 2008

Hand-foot and stump syndrome to sorafenib

artículo científico publicado en 2007

Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.

artículo científico publicado en 2011

Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients

artículo científico publicado en 2015

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients ⬇️

artículo científico publicado el 23 de agosto de 2010

Human papillomavirus-associated dysplastic condyloma of the tongue treated with Mohs micrographic surgery

artículo científico publicado en 2005

Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.

artículo científico publicado en 2017

Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results

artículo científico publicado en 2007

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

artículo científico publicado en 2017

Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic

artículo científico publicado en 2013

In reply

artículo científico publicado en 2013

Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis

artículo científico publicado en 2015

Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients

artículo científico publicado en 2015

Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.

artículo científico publicado en 2014

Incidence and risk of xerosis with targeted anticancer therapies

artículo científico publicado en 2015

Increased Airport Scrutiny by the Transportation Security Administration of a Patient-Passenger Carrying Ammonium Lactate-Containing Moisturizer

artículo científico publicado en 2016

Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy

artículo científico publicado en 2009

Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?

artículo científico publicado en 2011

Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor

artículo científico publicado en 2006

Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.

artículo científico publicado en 2007

Ipilimumab in patients with cancer and the management of dermatologic adverse events

artículo científico

KSHV/HHV8-associated primary cutaneous plasmablastic lymphoma in a patient with Castleman's disease and Kaposi's sarcoma

artículo científico publicado en 2006

Life-threatening dermatologic adverse events in oncology ⬇️

artículo científico publicado en 2014

Magnetic resonance imaging of paronychia induced by cetuximab

artículo científico publicado en 2009

Management of dermatologic toxicities

artículo científico publicado en 2015

Mechanisms of cutaneous toxicities to EGFR inhibitors.

artículo científico publicado en 2006

NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.

scientific article published on May 2009

Nasal vestibulitis due to targeted therapies in cancer patients.

artículo científico publicado en 2015

Necrobiotic xanthogranuloma associated with immunoglobulin m paraproteinemia in a patient with Waldenström macroglobulinemia

artículo científico publicado en 2011

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial

scientific article published on 06 February 2020

Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma

artículo científico publicado en 2007

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis

artículo científico publicado en 2017

Olmutinib-induced palmoplantar keratoderma.

artículo científico publicado en 2017

Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.

artículo científico publicado en 2017

Ossified soft tissue leiomyoma in a patient with sickle cell anemia

article

Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study

scientific article published on 19 December 2019

Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer

artículo científico publicado en 2014

Overview photography and short-term mole monitoring in patients taking a BRAF inhibitor.

artículo científico publicado en 2014

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

artículo científico publicado en 2015

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies ⬇️

artículo científico publicado el 17 de marzo de 2011

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

scientific article published on 26 February 2013

Photodermatosis associated with eculizumab (Soliris): a novel monoclonal antibody directed against the complement protein C5

artículo científico publicado en 2010

Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib

artículo científico publicado en 2007

Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

artículo científico publicado en 2017

Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib

artículo científico publicado en 2011

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients

artículo científico publicado en 2015

Post-reconstruction dermatitis of the breast.

artículo científico publicado en 2017

Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.

artículo científico publicado en 2011

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders

artículo científico publicado en 2014

Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.

artículo científico publicado en 2014

Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis

artículo científico publicado en 2013

Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.

artículo científico publicado en 2013

Quality Improvement in Management of Acute Coronary Syndrome: Continuing Medical Education and Peer Coaching Improve Antiplatelet Medication Adherence and Reduce Hospital Readmissions.

artículo científico publicado en 2017

Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.

artículo científico

Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization

artículo científico publicado en 2013

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors

artículo científico publicado en 2016

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

artículo científico publicado en 2015

Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies".

artículo científico publicado en 2015

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis

artículo científico publicado en 2013

Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.

artículo científico

Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis

artículo científico

Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis

artículo científico

Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials

artículo científico publicado en 2017

Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).

artículo científico publicado en 2009

Skin care for cancer patients

artículo científico publicado en 2012

Skin care management in cancer patients: an evaluation of quality of life and tolerability

artículo científico publicado en 2010

Skin rash in a transplant patient receiving multiple drugs.

artículo científico publicado en 2003

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

artículo científico publicado en 2010

Skin toxicity of targeted cancer agents: mechanisms and intervention.

artículo científico

Skinflammation and drug toxicity--a delicate balance

artículo científico publicado en 2013

Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.

artículo científico publicado en 2012

Stoma care products represent a common and previously underreported source of peristomal contact dermatitis

artículo científico publicado en 2016

T-DM1-related telangiectasias: a potential role in secondary bleeding events

artículo científico publicado en 2014

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

artículo científico publicado en 2015

Temporal dependence of the effect of radiation on erlotinib-induced skin rash

artículo científico publicado en 2007

The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome

scientific article published on 01 October 2006

The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.

artículo científico publicado en 2006

The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis.

artículo científico publicado en 2011

The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.

artículo científico publicado en 2012

The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies.

artículo científico publicado en 2011

The era of targeted therapies: increasing role for novel oncologic drugs in dermatology

scientific article published on 01 June 2007

The growing importance of skin toxicity in EGFR inhibitor therapy.

artículo científico publicado en 2009

The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies.

artículo científico publicado en 2005

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.

scientific article published on 11 March 2011

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

artículo científico publicado en 2013

The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.

artículo científico publicado en 2011

The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis

artículo científico publicado en 2015

The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.

artículo científico publicado en 2013

The role of inhibitors of the epidermal growth factor in management of head and neck cancer.

artículo científico publicado en 2008

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

artículo científico

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

artículo científico publicado en 2016

Tracking of second primary melanomas in vemurafenib-treated patients

artículo científico publicado en 2013

Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody

artículo científico publicado en 2005

Unanticipated toxicities from anticancer therapies: survivors' perspectives

artículo científico publicado en 2009

Utilization of magnetic elements in dentures

artículo científico publicado en 1979

Xerosis and pruritus as major EGFRI-associated adverse events.

artículo científico publicado en 2015

gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation

scientific article published on 01 May 2001

p63 in Primary Cutaneous Carcinosarcoma

scientific article published on 01 August 2007

reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial' by Cecc

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda